Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Chlorhexidine + cetylpyridinium chloride** is a combination of two cationic antiseptics commonly formulated in oral rinses and mouthwashes for reducing oral biofilm, gingivitis, periodontitis, halitosis, and peri-implant infections. Chlorhexidine is a bisbiguanide antiseptic with a broad-spectrum bactericidal action, disrupting bacterial cell membranes and causing leakage of cellular contents. Cetylpyridinium chloride is a quaternary ammonium compound that also disrupts microbial membranes and inhibits plaque formation. Combined, they show a synergistic antimicrobial effect against both gram-positive and gram-negative bacteria, and reduce the risk of adverse effects seen with higher concentrations of chlorhexidine. This combination also exhibits antiviral and antifungal properties, including inactivation activity against enveloped viruses such as influenza and coronaviruses. Main indication is adjunctive treatment in periodontal and peri-implant disease, and oral hygiene maintenance, including prophylaxis in dental procedures and management of oral biofilm[1][2][3][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorhexidine + cetylpyridinium chloride.